Bayesian sample size calculations in phase II clinical trials using informative conjugate priors

Controlled Clinical Trials

Volumn 25, Issue 2, 2004, Pages 157-167

  Mayo, Matthew S ^a   Gajewski, Byron J ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Beta; Binomial; Measure of location

Indexed keywords

ARTICLE; BAYES THEOREM; CALCULATION; CLINICAL TRIAL; DECISION MAKING; MATHEMATICAL ANALYSIS; PHASE 2 CLINICAL TRIAL; PROBABILITY; SAMPLE SIZE;

BAYES THEOREM; CLINICAL TRIALS, PHASE II; HUMANS; MODELS, STATISTICAL; PROBABILITY; SAMPLE SIZE; UNCERTAINTY;

EID: 1542291116     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2003.11.006     Document Type: Article

References (16)

1. Tan S.B., Machin D. Bayesian two-stage designs for phase II clinical trials. Stat. Med. 21:2002;1991-2012.
2. Gelman A., Carlin J.B., Stern H.S., Rubin D.B. Bayesian data analysis. 2000;Chapman & Hall, New York.
3. Thall P.F., Estey E.H. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation. Stat. Med. 12:1993;1197-1211.
4. Berry D.A. A case for Bayesianism in clinical trials. Stat. Med. 12:1993;1377-1393.
5. Thall P.F., Simon R. Practical guidelines for phase IIB clinical trials. Biometrics. 50:1994;337-349.
6. Lecoutre B., Derzko G., Grouin J.M. Bayesian predictive approach for inference and proportions. Stat. Med. 14:1995;1057-1063.
7. Abrams K., Ashby D., Errington D. Simple Bayesian analysis in clinical trials: a tutorial. Control. Clin. Trials. 15:1994;349-359.
8. Brunier H.C., Whitehead J. Sample sizes for phase II clinical trials derived from Bayesian decision theory. Stat. Med. 13:1994;2493-2502.
9. Thall P.F., Simon R.M., Estey E.H. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat. Med. 14:1995;357-379.
10. Thall P.F., Sung H.G. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat. Med. 17:1998;1563-1580.
11. Rosner G.L., Berry D.A. A Bayesian group sequential design for a multiple arm randomized clinical trial. Stat. Med. 14:1995;381-394.
12. Freedman L.S., Spiegelhalter D.J., Parmar M.K. The what, why, and how of Bayesian clinical trials monitoring. Stat. Med. 13:1994;1371-1383.
13. Carlin B.P., Sargent D.J. Robust approaches for clinical trial monitoring. Stat. Med. 15:1996;1093-1106.
14. Hensley M.L., Maki R., Venkatraman E.et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J. Clin. Oncol. 20:12:2002;2824-2831.
15. Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials. 10:1989;1-10.
16. Richardson P.G., Barlogie B., Berenson J.et al. A phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348:2003;2609-2617.